216 related articles for article (PubMed ID: 7913407)
1. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
2. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
3. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
5. Distinct responses of protein kinase C isozymes to c-erbB-2 activation in SKBR-3 human breast carcinoma cells.
Disatnik MH; Winnier AR; Mochly-Rosen D; Arteaga CL
Cell Growth Differ; 1994 Aug; 5(8):873-80. PubMed ID: 7986752
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.
Yen L; Nie ZR; You XL; Richard S; Langton-Webster BC; Alaoui-Jamali MA
Oncogene; 1997 Apr; 14(15):1827-35. PubMed ID: 9150389
[TBL] [Abstract][Full Text] [Related]
7. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
[TBL] [Abstract][Full Text] [Related]
8. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
10. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
Bai T; Luoh SW
Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
12. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
13. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
14. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
16. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
[TBL] [Abstract][Full Text] [Related]
17. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
Tuck AB; Hota C; Wilson SM; Chambers AF
Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
20. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
